| abstract |
The present invention relates to an oxa-azaspiro compound, a salt form thereof and a crystal form thereof, and in particular to a compound III and a pharmaceutically acceptable salt thereof, a crystal form of a salt form thereof, a preparation method therefor, and a use thereof as an LSD1 inhibitor in the treatment of diseases such as hematological tumors, small cell lung cancer, squamous non-small cell lung cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, glioma or Ewing's sarcoma. |